Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety

NCT01567995 | Completed Phase 3

• 1 other identifier: 111187
• Study Type: interventional
• Target: 240
• Locations: 1 country
• Sites: 7

Brief Summary

This was a multicenter, randomised, double-blind, two treatment arms, vehicle (cream base) -controlled, parallel-group study in subjects with moderate to severe eczema (defined by investigators global assessment (IGA) score greater than or equal to 3). Subjects were screened within 3 days prior to randomization. At the screen visit, subjects gave informed consent and were then assessed for health status and eligibility for inclusion in the study. At the baseline visit, subject eligibility was assessed for randomization (Day 0). Eligible subjects were randomised to Clobetasone Butyrate 0.05% Cream group or vehicle (cream base) group at the rate of 1:1. During the treatment phase, subjects returned to the sites in day 7 post-baseline visit for assessment of their disease status and eligibility to continue on the study. During the final visit, 14 days after the baseline, subjects returned to the study sites for assessment of their disease status before completing the study. In addition, the safety and tolerability of Clobetasone Butyrate 0.05% cream were also assessed through the whole trial.

Conditions

Eczema

Keywords

eczematous; dermatitis

Outcome Measures

Primary Outcomes (4)

• Change from baseline in Eczema Area and Severity Index (EASI) score at Day 7

  Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas using EASI: head/neck, upper limbs, trunk, and lower limbs. Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (\>90-100% eruption) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.

  Baseline, Day 7

• Change from baseline in Eczema Area and Severity Index (EASI) score at Day 14

  Investigators assessed presence and severity of erythema, induration/papulation, excoriation, and lichenification in four body areas using EASI: head/neck, upper limbs, trunk, and lower limbs. Investigators assigned a severity score from 0 - 3 for each area (none=0, mild=1, moderate=2, and severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (\>90-100% eruption) for each area. The weighting factor was 0.1 for head/neck, 0.2 for upper limbs, 0.3 for trunk, and 0.4 for lower limbs. The total body score for each body region was obtained by multiplying the sum of the severity scores of the four key signs by the area score, then multiplying the result by the constant weighted value assigned to that body region. The sum of these scores gave the EASI total, ranging from 0 to 72. A higher score represented greater disease severity. A negative change from baseline indicates improvement.

  Baseline, Day 14

• Reduction Percentage of Eczema Area and Severity Index (EASI) score after 7 day of treatment

  Investigator assessed surface \& severity of erythema, induration/papulation, excoriation \& lichenification in four body areas using EASI: head/neck, upper extremities, trunk \& lower extremities. Investigators assigned a severity score (0-3) for each area (none=0, mild=1, moderate=2, severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (\>90-100% eruption) for each area. Weighting factor was 0.1 for head/neck, 0.2 for upper extremities, 0.3 for trunk \& 0.4 for lower extremities. Total body score for each body region was obtained by multiplying sum of severity scores by area score, then multiplying result by constant weighted value assigned to that body region. Sum of these scores gave EASI total, ranging from 0 to 72. Reduction percentage of score was calculated as: (sum of score after day 7 minus sum of score at baseline) \*100/sum of score after day 7. Lesser negative reduction percentage lesser severity of disease, more effectiveness of treatment.

  up to Day 7

• Reduction Percentage of Eczema Area and Severity Index (EASI) score after 14 days of treatment

  Investigator assessed surface \& severity of erythema, induration/papulation, excoriation \& lichenification in four body areas using EASI: head/neck, upper extremities, trunk \& lower extremities. Investigators assigned a severity score (0-3) for each area (none=0, mild=1, moderate=2, severe=3). Investigators also assigned an area score from 0 (no eruption) to 6 (\>90-100% eruption) for each area. Weighting factor was 0.1 for head/neck, 0.2 for upper extremities, 0.3 for trunk \& 0.4 for lower extremities. Total body score for each body region was obtained by multiplying sum of severity scores by area score, then multiplying result by constant weighted value assigned to that body region. Sum of these scores gave EASI total, ranging from 0 to 72. Reduction percentage of score was calculated as: (sum of score after day 14 minus sum of score at baseline) \*100/sum of score after day 14. Lesser negative reduction percentage lesser severity of disease, more effectiveness of treatment.

  up to Day 14

Secondary Outcomes (3)

• Change from baseline in Investigators Global Assessment (IGA) graded score at Day 7 and Day 14

  Baseline, Day 7 and Day 14

• Changes from baseline in Visual Analog Scale (VAS) at Day 7 and Day 14

  Baseline, Day 7 and Day 14

• Number of participants with participants-based assessment score of disease control at Day 7 and Day 14

  Day 7 and Day 14

Study Arms (2)

Clobetasone Butyrate 0.05% Cream

EXPERIMENTAL

Clobetasone Butyrate 0.05% Cream

Drug: Clobetasone Butyrate 0.05% Cream

Vehicle (base cream)

OTHER

Vehicle (base cream)

Drug: Vehicle (base cream)

Interventions

Clobetasone Butyrate 0.05% Cream DRUG

Clobetasone Butyrate 0.05% Cream

Clobetasone Butyrate 0.05% Cream

Vehicle (base cream) DRUG

Vehicle (base cream)

Vehicle (base cream)

Eligibility Criteria

• Age: 12 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects with a diagnosis of eczema, fulfil the 3 follow items: 1) Erythema, papilla/water blister, Lichenification, skin damage with infiltration, 2) unknown reason, recurrent attacks; 3) itching in diseased skin
• Subjects must have body surface area (BSA) disease involvement of less than or equal to 10% as assessed by palm method
• Subject must present with moderate and above eczema as defined by a score greater than or equal to 3 using the investigators global assessment (IGA) of eczema severity.

You may not qualify if:

• The subject presents with any systemic disorder or active skin disease (e.g. psoriasis) that would in any way confound interpretation of the study results or subjects who present with scars, moles, tattoos, body piercings, sunburn in the test area which could interfere with the assessment of lesions at screening.
• The subject has eczema restricted to the face, the feet or the hands only.
• The subject is indicated any anti-infectives drug for a current complication of overt bacterial, fungal and viral infection
• History of recent (\<1 month) active or presence of current superficial skin infections of viral aetiology such as herpes simplex, or varicella.
• The subject has been exposed to below therapy within the set timeframe: Topical agents administered in the diseased skin, including emollient - 1 week; Systemic administration of anti-histamine agents - 2 week; Systemic administration of corticosteroid -4 week; Systemic administration of immunosuppressive drugs - 4 week; UV therapy -4 week
• Foreseeable intensive ultraviolet (UV) exposure during the study (solar or artificial). Subjects must not be exposed to intense direct sunlight for long periods, and must not use skin tanning devices (e.g. sunbed) for the duration of the study.
• History of clinically significant cardiovascular, pulmonary, gastrointestinal, liver, neurological, renal or haematological abnormalities.
• History of allergy to components of test medications to be used in the study.
• History of anaphylaxis (a sudden, potentially life-threatening systemic allergic reaction) to food, medications, insect venom, or latex.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (7)

GSK Investigational Site

Nanjing, Jiangsu, 210029, China

Location

GSK Investigational Site

Nanjing, Jiangsu, 210042, China

Location

GSK Investigational Site

Beijing, 100034, China

Location

GSK Investigational Site

Beijing, 100044, China

Location

GSK Investigational Site

Beijing, 100730, China

Location

GSK Investigational Site

Shanghai, 200040, China

Location

GSK Investigational Site

Tianjin, 300052, China

Location

MeSH Terms

Conditions

Eczema; Dermatitis

Interventions

clobetasone butyrate

Condition Hierarchy (Ancestors)

Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 29, 2012
• First Posted: April 2, 2012
• Study Start: February 28, 2008
• Primary Completion: January 1, 2009
• Study Completion: February 10, 2009
• Last Updated: November 28, 2017

Record last verified: 2017-11

Locations

CN (7)